Blog
About

113
views
0
recommends
+1 Recommend
1 collections
    8
    shares
    • Record: found
    • Abstract: found
    • Article: found
    Is Open Access

    To TAVR or Not to TAVR

    , MD, MACC

    Cardiovascular Innovations and Applications

    Compuscript

    Read this article at

    ScienceOpenPublisher
    Bookmark
        There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

        Related collections

        Most cited references 1

        • Record: found
        • Abstract: found
        • Article: found
        Is Open Access

        Will Transcatheter Aortic Valve Replacement (TAVR) be the Primary Therapy for Aortic Stenosis?

         Jose Condado,  Peter C Block (corresponding) (2016)
        Transcatheter aortic valve replacement (TAVR) is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis (AS) or failing surgical bioprosthesis (valve-in-valve, VIV-TAVR). In TAVR, the collapsed transcatheter heart valve (THV) is introduced using the delivery system inserted from the femoral artery (preferred) or other alternative accesses (transapical, transaortic, transcarotid, subclavian/transinnominate or transcaval). The delivery system is then advanced until coaxially aligned with the aortic annulus, where the THV is deployed. This procedure can be associated with complications such as access site injury (vascular complication), paravalvar leak, cerebrovascular events and conduction disturbances. However, the rapid acceptance and successes observed with TAVR have been made possible through careful patient selection, preprocedural planning (i.e. MDCT annular sizing), THV technology (i.e. new generation valves), and procedural techniques (i.e. minimalist TF-TAVR and alternative percutaneous access options), as well as a decrease in complications as TAVR experience grows. Though the results or ongoing clinical trials evaluating TAVR in intermediate surgical risk patients are pending, it is likely that TAVR will soon be approved for lower risk patients as well.
          Bookmark

          Author and article information

          Author notes
          Correspondence: C. Richard Conti, MD, MACC, Department of Medicine, University of Florida, Gainesville, FL 32610, USA, E-mail: richard.conti@ 123456medicine.ufl.edu
          Journal
          CVIA
          Cardiovascular Innovations and Applications
          CVIA
          Compuscript (Ireland )
          2009-8782
          2009-8618
          May 2017
          July 2017
          : 2
          : 3
          : 403-405
          cvia20160053 10.15212/CVIA.2016.0053
          Copyright © 2017 Cardiovascular Innovations and Applications

          This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

          Product
          Categories
          Commentaries

          Comments

          Comment on this article